Quarterly ResultMay 11, 2026, 04:07 PM
Kyntra Bio Q1 Results; FG-3246 Phase 2 Progress; Roxadustat Phase 3 Finalized
AI Summary
Kyntra Bio reported its first quarter 2026 financial results, showing increased revenue and a reduced net loss compared to the prior year. The company also provided positive updates on its pipeline, with the Phase 2 trial of FG-3246 progressing towards an interim analysis in Q4 2026 and the pivotal Phase 3 trial protocol for roxadustat being finalized with FDA feedback for a 2H 2026 initiation. Kyntra Bio maintains a strong financial position with $100.3 million in cash and equivalents, providing a runway into 2028.
Key Highlights
- Q1 2026 total revenue from continuing operations was $3.7 million, up from $2.7 million in Q1 2025.
- Q1 2026 net loss from continuing operations was $15.1 million, an improvement from $16.8 million in Q1 2025.
- Cash, cash equivalents, investments, and accounts receivable totaled $100.3 million as of March 31, 2026.
- Company expects cash runway into 2028.
- Phase 2 monotherapy trial of FG-3246 in mCRPC is on track for interim analysis in 4Q 2026.
- Investigator-sponsored study of FG-3246 + enzalutamide showed median rPFS of 7.0 months overall, 10.1 months in specific mCRPC patients.
- Pivotal Phase 3 trial protocol of roxadustat for LR-MDS is being finalized with FDA feedback.
- Roxadustat Phase 3 trial initiation is anticipated in the second half of 2026.